Allarity Therapeutics’ (ALLR) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Allarity Therapeutics (NASDAQ:ALLR) in a research report released on Wednesday morning,Weiss Ratings reports.

A number of other equities research analysts have also recently weighed in on the stock. Ascendiant Capital Markets lifted their price objective on shares of Allarity Therapeutics from $9.00 to $9.25 and gave the company a “buy” rating in a research note on Friday, September 26th. Wall Street Zen upgraded shares of Allarity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $9.25.

Allarity Therapeutics Stock Performance

Shares of NASDAQ ALLR opened at $1.61 on Wednesday. Allarity Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $2.35. The firm’s 50-day simple moving average is $1.43 and its 200 day simple moving average is $1.13.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings data on Friday, August 15th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. On average, sell-side analysts expect that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Allarity Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Allarity Therapeutics in the 2nd quarter worth about $51,000. Geode Capital Management LLC increased its stake in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after purchasing an additional 16,729 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Allarity Therapeutics in the 2nd quarter worth about $27,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.